NCT04918108 is a clinical trial of inflammatory response in Aortic Dissection, sponsored by Nanjing Medical University.

Who is sponsoring NCT04918108?

NCT04918108 is sponsored by Nanjing Medical University.

What drugs are being tested in NCT04918108?

Interventions in NCT04918108: inflammatory response.

What condition does NCT04918108 study?

NCT04918108 studies Aortic Dissection.

Is NCT04918108 still recruiting?

NCT04918108 is currently completed. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT04918108

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III

Completed Last updated 20 November 2024

What this trial tests

trial testing inflammatory response in Aortic Dissection in 2,000 participants. Completed in 30 August 2021.

Timeline

1 January 2021

Primary endpoint
30 August 2021

30 August 2021

Quick facts

Lead sponsor	Nanjing Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 January 2021
Primary completion	30 August 2021
Estimated completion	30 August 2021
Sites	1 location across China

Drugs / interventions tested

inflammatory response — full drug profile →

Conditions studied

Aortic Dissection — all drugs for Aortic Dissection →

Sponsor

Nanjing Medical University

Who can join

Adults 18 to 90, any sex, with Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. The authors evaluated the inflammatory response in patients with aortic dissection (AD) and assessed the presence of distinct inflammatory subphenotypes within this disease.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic Impact of Systemic Coagulation-Inflammation Index in Acute Type A Aortic Dissection Surgery.
Liu H, Qian SC, Shao YF, Li HY, et al · · 2022 · cited 25× · PMID 36444319 · DOI 10.1016/j.jacasi.2022.06.007
Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection.
Liu H, Qian SC, Shao YF, Li HY, et al · · 2022 · cited 14× · PMID 35783246 · DOI 10.2147/jir.s369703
A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy Score.
Liu H, Qian SC, Zhang YY, Wu Y, et al · · 2022 · cited 12× · PMID 36185465 · DOI 10.1016/j.mayocpiqo.2022.08.005
Circulating biomarker-based risk stratifications individualize arch repair strategy of acute Type A aortic dissection via the XGBoosting algorithm.
Liu H, Qian SC, Han L, Zhang YY, et al · · 2022 · cited 9× · PMID 36710897 · DOI 10.1093/ehjdh/ztac068
Proximal vs Extensive Repair in Acute Type A Aortic Dissection Surgery.
Liu H, Zhang YY, Ding XH, Qian SC, et al · · 2023 · cited 8× · PMID 37105511 · DOI 10.1016/j.athoracsur.2023.04.019
Laboratory signatures differentiate the tolerance to hypothermic circulatory arrest in acute type A aortic dissection surgery.
Liu H, Qian SC, Han L, Dong ZQ, et al · · 2022 · cited 3× · PMID 36271847 · DOI 10.1093/icvts/ivac267

Verify or expand the search:

Other recruiting trials for Aortic Dissection

Currently open trials in the same condition.

NCT06550986 — False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study · NA · recruiting
NCT06968806 — Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection · Phase 3 · recruiting
NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
NCT06915545 — Study on the Aortic Arch Single Branch Stent Graft System · NA · recruiting
NCT07117825 — Aortic Dissection fAlse enlarGement radIomics predictiOn · active not recruiting

Other Nanjing Medical University trials

Trials by the same sponsor.

NCT07382375 — AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection · NA · not yet recruiting
NCT07494474 — Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD · not yet recruiting
NCT07482774 — Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma · not yet recruiting
NCT07348328 — Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery · NA · not yet recruiting
NCT07258394 — Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04918108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing Medical University
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing